A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer

被引：3
|
作者：
Huff, Amanda L.
Haldar, Saurav D.
Davis-Marcisak, Emily
Heumann, Thatcher
Longway, Gabriella
Hernandez, Alexei
Konig, Maximillian F.
Mog, Brian
Danilova, Ludmila
Kagohara, Luciane
Nauroth, Julie M.
Thomas, Amy M.
Fertig, Elana J.
Ho, Won Jin
Jaffee, Elizabeth M.
Azad, Nilo
Zaidi, Neeha
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Cancer vaccine induces potent T cell responses - but is it enough?
    Rohatgi, Anjali
    Kirkwood, John M.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (12) : 721 - 722
  • [32] Synthetic peptide vaccine strategies for the enhancement of cytotoxic T-cell responses
    Dakappagari, Naveen K.
    Sundaram, Roshni
    Rawale, Sharad
    Kaumaya, Pravin T. P.
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 989 - 990
  • [33] Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer
    Christmas, Brian
    Scott, Blake
    Armstrong, Todd
    Azad, Nilofer
    Jaffee, Elizabeth
    CANCER RESEARCH, 2017, 77
  • [34] Phase II clinical trial using novel peptide vaccine cocktail as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Yamaue, Hiroki
    Miyazawa, Motoki
    Katsuda, Masahiro
    Maguchi, Hiroyuki
    Ishii, Hiroshi
    Yamao, Kenji
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-Ichi
    Shimizu, Atsushi
    Kitahata, Yuji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Neoantigen adenoviral cancer vaccine generates improved CD8+ T-cell responses compared to adjuvanted peptide vaccine
    Dagotto, Gabriel
    Colarusso, Alessandro
    Patio, Robert
    Li, David
    Anioke, Tochi
    Giffin, Victoria
    Aid, Malika
    Barouch, Dan
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
  • [36] Immunotherapeutic role of mutant ras peptide-based vaccine as an adjuvant in pancreatic and colorectal cancer.
    Toubaji, A
    Achtar, MS
    Herrin, VE
    Provenzano, M
    Bernstein, S
    Brent-Steel, T
    Marincola, F
    Khleif, SN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 184S - 184S
  • [37] Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses
    Bazzill, Joseph D.
    Stronsky, Sabrina M.
    Kalinyak, Laura C.
    Ochyl, Lukasz J.
    Steffens, Jesse T.
    van Tongeren, Sean A.
    Cooper, Christopher L.
    Moon, James J.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2019, 18 : 414 - 425
  • [38] TELOMERASE-PEPTIDE VACCINE TOGETHER WITH GEMCITABINE IN ADVANCED PANCREATIC CANCER PATIENTS
    Staff, C. E. B.
    Mozaffari, F. M.
    Liljefors, M.
    Mosolits, S.
    Frodin, J.
    Choudhury, A.
    Mellstedt, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 26 - 26
  • [39] PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients
    Gong Mengyuan
    Zhang Bo
    Wang Xueni
    Zhu Zeen
    Li Wei
    Han Liang
    Wu Zheng
    Ma Qingyong
    Wang Zheng
    Qian Weikun
    胰腺病学杂志（英文）, 2024, 07 (03)
  • [40] PSCA is a critical biomarker for predicting the prognosis of KRAS/TP53 mutant pancreatic cancer patients
    Gong, Mengyuan
    Zhang, Bo
    Wang, Xueni
    Zhu, Zeen
    Li, Wei
    Han, Liang
    Wu, Zheng
    Ma, Qingyong
    Wang, Zheng
    Qian, Weikun
    JOURNAL OF PANCREATOLOGY, 2024, 7 (03) : 191 - 198
12345